List view / Grid view
14 November 2014 | By MedImmune and Advaxis
Dose confirmation safety study of ADXS-HPV and MEDI4736 combination therapy to initiate in early 2015...
14 November 2014 | By GlaxoSmithKline
GSK launched the first call for proposals for its Africa NCD Open Lab, to support much-needed scientific research into non-communicable diseases (NCDs) in Africa...
14 November 2014 | By Bristol-Myers Squibb
Bristol-Myers Squibb Company announced plans to construct a new state-of-the-art, large-scale biologics manufacturing facility in Cruiserath, County Dublin, Ireland, that will produce multiple therapies for the company’s growing biologics portfolio...
14 November 2014 | By Genticel
Genticel, a French biotechnology company and leading developer of therapeutic vaccines, announces the completion of patient enrollment of the phase II study of its lead therapeutic vaccine candidate, ProCervix...
14 November 2014 | By Moberg Pharma
Moberg Pharma’s partner in Southeast Asia and China, Menarini APAC, has initiated the launch in Malaysia of Moberg Pharma’s prescription-free treatment for nail fungus...
14 November 2014 | By Roche
The cobas Strep A test is the first molecular point of care test to provide a result in 15 minutes for this common infection...
13 November 2014 | By SELECTBIO
SELECTBIO is delighted to announce that Screening Europe is back...
Leader in contract bio/pharma industry intelligence predicts ongoing in-house manufacture...
13 November 2014 | By Bristol-Myers Squibb
Bristol-Myers Squibb Company announced that 16 abstracts for Orencia were accepted for presentation at the 2014 annual meeting of the American College of Rheumatology (ACR) taking place from November 14-19, 2014 in Boston, MA...
13 November 2014 | By Gilead Sciences
High cure rates in nearly 800 Hepatitis C Virus (HCV patients with advanced liver disease)...
13 November 2014 | By Frost & Sullivan
Cloud service providers that offer guaranteed reliability and clear data portability terms will emerge as top contenders, finds Frost & Sullivan...
13 November 2014 | By British Generic Manufacturers Association
Price cuts for branded generic medicines as part of proposed Government changes to the statutory scheme to control the prices of branded health service medicines will undermine innovation, create uncertainty, reduce competition and ultimately undermine patient benefits...
13 November 2014 | By ABIVAX
ABIVAX, a leading European, clinical stage biopharmaceutical company developing and commercializing anti-viral compounds and human vaccines, announced that it has signed an agreement with The Finlay Institute, Havana, Cuba...
12 November 2014 | By TiGenix NV
TiGenix NV announced that it has completed the patient recruitment for its Phase III trial of Cx601 in Europe for the treatment of complex perianal fistulas in Crohn's patients...
12 November 2014 | By GlobalData
Biologics will play an influential role in shaping the future of cardiovascular (CV) drug treatment, as these and other emerging therapies will compete for patients who cannot tolerate statins, or for whom statin therapy alone is insufficient, according to an analyst with research and consulting firm GlobalData...
